| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| review article | Q7318358 |
| systematic review | Q1504425 |
| P50 | author | Geertruida H de Bock | Q37842361 |
| P2093 | author name string | Gijs W D Landman | |
| Henk J G Bilo | |||
| Klaas H Groenier | |||
| Kornelis J J van Hateren | |||
| Nanne Kleefstra | |||
| Peter R van Dijk | |||
| Rijk O B Gans | |||
| Sebastiaan T Houweling | |||
| P2860 | cites work | A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial | Q46401187 |
| The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). | Q46747388 | ||
| Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes | Q46955559 | ||
| Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. | Q51561873 | ||
| Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. | Q51611008 | ||
| Is this clinical trial fully registered?--A statement from the International Committee of Medical Journal Editors. | Q53272988 | ||
| Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning | Q54062802 | ||
| Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors | Q55894706 | ||
| Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study | Q68950036 | ||
| Glibenclamide vs gliclazide in type 2 diabetes of the elderly | Q72642540 | ||
| Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes | Q78044125 | ||
| Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas | Q93558538 | ||
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 | ||
| Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus | Q24236456 | ||
| GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients | Q28276621 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects | Q33387180 | ||
| Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes | Q33423005 | ||
| Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study | Q33508039 | ||
| Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis | Q34031108 | ||
| Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study | Q34158078 | ||
| Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone | Q35038326 | ||
| Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions | Q35080218 | ||
| Variations in tissue selectivity amongst insulin secretagogues: a systematic review | Q37933466 | ||
| KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update | Q39535980 | ||
| ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage | Q41164062 | ||
| Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. | Q42145971 | ||
| Severe hypoglycemia and risks of vascular events and death | Q42868535 | ||
| A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study | Q43034890 | ||
| Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes | Q43286552 | ||
| Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients | Q43427440 | ||
| Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents | Q44665362 | ||
| Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes | Q44705128 | ||
| Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study | Q44802551 | ||
| Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study | Q45074002 | ||
| Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels | Q46218245 | ||
| Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study | Q46302371 | ||
| Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia | Q46354523 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | urea | Q48318 |
| gliclazide | Q290001 | ||
| systematic review | Q1504425 | ||
| type 2 diabetes | Q3025883 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e82880 | |
| P577 | publication date | 2014-01-01 | |
| 2014-02-12 | |||
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials | |
| P478 | volume | 9 |
| Q31137238 | A Systematic Review of Methods for Handling Missing Variance Data in Meta-Analyses of Interventions in Type 2 Diabetes Mellitus |
| Q37456636 | Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39). |
| Q53519441 | Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). |
| Q64105285 | Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials |
| Q90576443 | Fasting insulin levels correlate with the frequency of hypoglycemic events in people with type 2 diabetes on treatment with sulfonylureas: A pilot study |
| Q26752669 | Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence |
| Q38754132 | Is gliclazide a sulfonylurea with difference? A review in 2016. |
| Q26783199 | Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement |
| Q37571899 | Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes |
| Q92263945 | Radioprotective Effect of Gliclazide as an Anti-Hyperglycemic Agent Against Genotoxicity Induced by Ionizing Radiation on Human Lymphocytes |
| Q90395295 | Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea |
| Q37238060 | Temporal trends in the use of antidiabetic medicines: a nationwide 9-year study in older people living in New Zealand. |
| Q51244981 | Thiazolidinediones versus metformin on improving abnormal liver enzymes in patients with type 2 diabetes mellitus: a meta-analysis. |
| Q36057918 | Within-Sulfonylurea-Class Evaluation of Time to Intensification with Insulin (ZODIAC-43). |
| Q33830390 | Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) - a study protocol. |
| Q86976884 | Within-class differences of the sulfonylureas should be accounted for |
| Q91998763 | [Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes] |
Search more.